1.What are the drug quality issues that this country is facing?

 Counterfeit, substandard, expired products,  Mislabeled products,  False claims, etc.

2. What is the impact of these issues?

 Waste of resources,  collapse of faith in the government,  prolonged illnesses,  death,  exacerbated drug resistance, etc.

3. What other quality issues might the country face?

 LVP  SVP  vaccines  blood products, etc.

4. What are some of the country’s options for improving the quality of drugs entering the public and private sectors?

 National essential medicines list,  registration of products,  inspection at primary ports of entry especially airports,  tiered product testing at POE,  tightening of supply chains

5. Who are the stakeholders in drug quality?

 All of the health sector including:  suppliers  dispensers,  physicians,  pharmacists,  patients.

6. How can they work together it improve the enforcement of quality?

 Report all apparent deviations in product quality—off color, broken or powdery tablets, poor labeling.

7. What type of support might the government seek from donors?

 Development of a National Drug Policy including training for drug registration, inspectors, laboratory personnel  Establishment of a Minilab network at POE  Equipping a proper central drug laboratory  National Pharmacovigilance Information Center